๐ฐ Temporary Equity News
Temporary Equity News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Temporary Equity. Real-time updates on events, politics, business and more.
May 7, 2024
First quarter 2024 Total Revenue increased 24% year-over-year to $271.7 million First quarter 2024 Written Premium increased 19% year-over-year to $218.3...
March 27, 2024
Verint Announces Q4 FYE 2024 Results Revenue and Diluted EPS Come in Ahead of Guidance Raising Revenue and EPS Outlook for...
March 27, 2024
Revenue and Diluted EPS Come in Ahead of Guidance Raising Revenue and EPS Outlook for FYE25 AI-Powered Open Platform Resonating Well in the Market Driving Bundled SaaS Momentum ...
February 23, 2024
/PRNewswire/ - RB Global, Inc. (NYSE: RBA) & (TSX: RBA), the "Company", "RB Global", "we", "us", "their", or "our") reported the following results for the...
February 20, 2024
20.02.2024 - RingCentral, Inc. (NYSE:RNG), a leading provider of AI-driven cloud business communications, contact center, video and hybrid event solutions, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023. Fourth ...
January 29, 2024
29.01.2024 - SoFi Technologies, Inc. (NASDAQ: SOFI), a member-centric, one-stop shop for digital financial services that helps members borrow, save, spend, invest and protect their money, reported financial results today for its fourth quarter and fiscal year ...
January 23, 2024
TALLAHASSEE, Fla., Jan. 23, 2024 -- Capital City Bank Group, Inc. today reported net income attributable to common shareowners of $11.7 million, or $0.70 per diluted share, for the fourth quarter...
December 6, 2023
SaaS ARR up 11% Year-Over-Year Driven by Solid Bookings and Renewals Positive Leading Indicators with Significant Increase in Customer AI Adoption and SaaS Pipeline up More than 20%...
November 14, 2023
- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track ...
November 14, 2023
Key Corporate Highlights: Progressing toward Q1-2024 initiation of a proof-of-concept clinical trial with Cholesterol Efflux Mediatorโข VAR 200 in patients with diabetic kidney disease...